CARD16 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	34 studies	34% ± 11%	Explore
macrophage	27 studies	33% ± 14%	Explore
classical monocyte	26 studies	52% ± 17%	Explore
conventional dendritic cell	25 studies	37% ± 17%	Explore
CD8-positive, alpha-beta T cell	25 studies	25% ± 10%	Explore
non-classical monocyte	23 studies	69% ± 17%	Explore
regulatory T cell	23 studies	43% ± 14%	Explore
CD4-positive, alpha-beta T cell	20 studies	21% ± 5%	Explore
monocyte	19 studies	45% ± 13%	Explore
endothelial cell	18 studies	29% ± 12%	Explore
T cell	17 studies	24% ± 5%	Explore
mature NK T cell	16 studies	29% ± 10%	Explore
dendritic cell	15 studies	36% ± 16%	Explore
gamma-delta T cell	15 studies	26% ± 7%	Explore
CD16-positive, CD56-dim natural killer cell, human	13 studies	42% ± 13%	Explore
B cell	12 studies	21% ± 4%	Explore
endothelial cell of lymphatic vessel	11 studies	24% ± 10%	Explore
CD16-negative, CD56-bright natural killer cell, human	11 studies	31% ± 11%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	10 studies	22% ± 5%	Explore
endothelial cell of artery	9 studies	23% ± 7%	Explore
neutrophil	8 studies	41% ± 13%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	8 studies	20% ± 4%	Explore
mucosal invariant T cell	8 studies	27% ± 7%	Explore
myeloid cell	8 studies	32% ± 12%	Explore
CD8-positive, alpha-beta memory T cell	7 studies	29% ± 14%	Explore
capillary endothelial cell	7 studies	26% ± 5%	Explore
naive B cell	7 studies	20% ± 4%	Explore
vein endothelial cell	7 studies	26% ± 12%	Explore
effector CD8-positive, alpha-beta T cell	6 studies	30% ± 9%	Explore
effector memory CD8-positive, alpha-beta T cell	6 studies	30% ± 6%	Explore
alveolar macrophage	5 studies	33% ± 7%	Explore
platelet	5 studies	23% ± 7%	Explore
mononuclear phagocyte	5 studies	44% ± 15%	Explore
fibroblast	5 studies	23% ± 2%	Explore
endothelial cell of vascular tree	5 studies	26% ± 7%	Explore
innate lymphoid cell	5 studies	30% ± 8%	Explore
memory B cell	5 studies	20% ± 3%	Explore
effector CD4-positive, alpha-beta T cell	5 studies	32% ± 12%	Explore
intermediate monocyte	5 studies	61% ± 24%	Explore
CD4-positive, alpha-beta memory T cell	5 studies	28% ± 7%	Explore
leukocyte	4 studies	23% ± 5%	Explore
monocyte-derived dendritic cell	4 studies	46% ± 22%	Explore
exhausted T cell	4 studies	36% ± 10%	Explore
epithelial cell	4 studies	29% ± 9%	Explore
effector memory CD4-positive, alpha-beta T cell	4 studies	32% ± 5%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	4 studies	29% ± 7%	Explore
plasmablast	3 studies	32% ± 17%	Explore
plasmacytoid dendritic cell	3 studies	23% ± 4%	Explore
hematopoietic precursor cell	3 studies	21% ± 2%	Explore
glomerular endothelial cell	3 studies	25% ± 4%	Explore
enterocyte	3 studies	19% ± 3%	Explore
immature B cell	3 studies	23% ± 5%	Explore
connective tissue cell	3 studies	26% ± 9%	Explore
T follicular helper cell	3 studies	24% ± 7%	Explore
T-helper 17 cell	3 studies	20% ± 2%	Explore
T-helper 1 cell	3 studies	26% ± 6%	Explore
double negative thymocyte	3 studies	29% ± 4%	Explore
basal cell	3 studies	22% ± 5%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	17 studies	35% ± 9%	Explore
lung	11 studies	23% ± 7%	Explore
lymph node	3 studies	20% ± 4%	Explore
intestine	3 studies	19% ± 2%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	100%	1159.31	578 / 578	98%	14.79	1132 / 1155
ovary	100%	256.97	180 / 180	95%	12.68	408 / 430
stomach	97%	205.59	349 / 359	98%	15.70	279 / 286
intestine	96%	433.86	930 / 966	98%	14.73	518 / 527
breast	99%	280.19	456 / 459	90%	10.43	1004 / 1118
uterus	95%	169.96	162 / 170	92%	13.42	420 / 459
esophagus	89%	167.67	1281 / 1445	97%	13.53	178 / 183
kidney	100%	255.79	89 / 89	85%	14.49	766 / 901
skin	95%	196.85	1713 / 1809	87%	26.58	412 / 472
thymus	96%	205.08	630 / 653	84%	8.36	511 / 605
bladder	86%	270.00	18 / 21	87%	12.16	437 / 504
liver	81%	121.51	182 / 226	81%	7.27	328 / 406
prostate	97%	205.91	237 / 245	61%	3.78	308 / 502
adrenal gland	93%	138.61	241 / 258	56%	4.42	128 / 230
pancreas	22%	24.57	73 / 328	92%	14.58	164 / 178
lymph node	0%	0	0 / 0	100%	38.95	29 / 29
spleen	100%	1857.36	241 / 241	0%	0	0 / 0
adipose	100%	356.46	1200 / 1204	0%	0	0 / 0
peripheral blood	99%	980.23	924 / 929	0%	0	0 / 0
tonsil	0%	0	0 / 0	93%	11.62	42 / 45
heart	91%	152.58	787 / 861	0%	0	0 / 0
brain	39%	45.25	1037 / 2642	51%	7.34	363 / 705
blood vessel	77%	146.77	1029 / 1335	0%	0	0 / 0
eye	0%	0	0 / 0	41%	4.47	33 / 80
muscle	16%	15.64	132 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0043154	Biological process	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO_0050727	Biological process	regulation of inflammatory response
GO_0032691	Biological process	negative regulation of interleukin-1 beta production
GO_0051092	Biological process	positive regulation of NF-kappaB transcription factor activity
GO_0043123	Biological process	positive regulation of canonical NF-kappaB signal transduction
GO_0031665	Biological process	negative regulation of lipopolysaccharide-mediated signaling pathway
GO_0071222	Biological process	cellular response to lipopolysaccharide
GO_0097340	Biological process	inhibition of cysteine-type endopeptidase activity
GO_0032091	Biological process	negative regulation of protein binding
GO_0010804	Biological process	negative regulation of tumor necrosis factor-mediated signaling pathway
GO_0072559	Cellular component	NLRP3 inflammasome complex
GO_0072557	Cellular component	IPAF inflammasome complex
GO_0032991	Cellular component	protein-containing complex
GO_0097169	Cellular component	AIM2 inflammasome complex
GO_0097179	Cellular component	protease inhibitor complex
GO_0050700	Molecular function	CARD domain binding
GO_0004869	Molecular function	cysteine-type endopeptidase inhibitor activity
GO_0019900	Molecular function	kinase binding
GO_0042802	Molecular function	identical protein binding
GO_0089720	Molecular function	caspase binding
GO_0005515	Molecular function	protein binding

IV. Literature review

[source]

Gene name	CARD16
Protein name	Caspase recruitment domain-containing protein 16 (Caspase recruitment domain-only protein 1) (CARD-only protein 1) (Caspase-1 inhibitor COP) (Pseudo interleukin-1 beta converting enzyme) (Pseudo-ICE) (Pseudo-IL1B-converting enzyme) Caspase recruitment domain family member 16
Synonyms	COP1 COP
Description	FUNCTION: Caspase inhibitor. Acts as a regulator of procaspase-1/CASP1 activation implicated in the regulation of the proteolytic maturation of pro-interleukin-1 beta (IL1B) and its release during inflammation. Inhibits the release of IL1B in response to LPS in monocytes. Also induces NF-kappa-B activation during the pro-inflammatory cytokine response. Also able to inhibit CASP1-mediated neuronal cell death, TNF-alpha, hypoxia-, UV-, and staurosporine-mediated cell death but not ER stress-mediated cell death. Acts by preventing activation of caspases CASP1 and CASP4, possibly by preventing the interaction between CASP1 and RIPK2. .
Accessions	Q5EG05 ENST00000528513.1 ENST00000672037.1 [Q5EG05-1] ENST00000673097.2 [Q5EG05-2] A0A8I5KS59

CARD16 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review